Showing results (171-180 of 202) with videos related to

Sort By:
Pageof 21
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trialA Gennari, Z Sun, U Hasler-Strub, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 18, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)L Malorni, S Tyekucheva, A Gombos, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTOS Di Cosimo, C Campbell, H A Azim, et al.
Breast (Edinburgh, Scotland)|June 22, 2026
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancerL Gianni, S Delaloge, E Ciruelos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerR Dent, F André, A Gonçalves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2026
A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 studyL Garrigós, M Ruiz-Borrego, J M Pérez-García, et al.
Nature Communications|May 13, 2022
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancerM G Filippone, D Gaglio, R Bonfanti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trialM Dugo, C-S Huang, D Egle, et al.
Pageof 21